Literature DB >> 16092116

Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease.

Katherine A Grosset1, John L Reid, Donald G Grosset.   

Abstract

Management of Parkinson's disease (PD) depends primarily on oral medication. There are several drug classes and multiple doses and formulations, which make optimizing therapy complex. Variable drug absorption and the short half-life of most antiparkinson treatments, especially levodopa, are a main focus in understanding complications and have encouraged alternative delivery systems to limit fluctuation and dyskinesia at later stages. Comparatively little attention is paid to the way patients take their oral medication. Variable medicine-taking behavior can affect the clinician's understanding of the diagnosis and rate of progression, and further prescription of PD medication. Medicine overuse in later stage PD is well documented and causes psychiatric disturbance and increases motor complications, but evidence of undertreatment and erratic intake is emerging, which is likely to affect motor control and quality of life adversely. Methods of quantifying compliance are compared for accuracy and limitations. Understanding medicine-taking behavior is a first step in optimizing therapy and requires consideration of a patient's personal beliefs about their medicines. Although the benefits of regularizing oral medicine-taking in a practical, achievable way in PD remain untested, such an approach might prolong and smooth the benefits of oral medication and is worthy of further research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16092116     DOI: 10.1002/mds.20525

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  26 in total

Review 1.  Medication nonadherence in Parkinson's disease.

Authors:  Jori E Fleisher; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

2.  Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

Authors:  Huybert Groenendaal; Marcy L Tarrants; Christophe Armand
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Medication adherence in patients with Parkinson's disease.

Authors:  Naveed Malek; Donald G Grosset
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

4.  Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.

Authors:  Maurits E L Arbouw; Kris L L Movig; Toine C G Egberts; Petra J E Poels; Jeroen P P van Vugt; Judith A M Wessels; R J H M van der Straaten; Cees Neef; Henk-Jan Guchelaar
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

5.  Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials.

Authors:  Maurits E L Arbouw; Kris L L Movig; Henk-Jan Guchelaar; Petra J E Poels; Jeroen P P van Vugt; Cees Neef; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2008-07-15       Impact factor: 2.953

Review 6.  Challenges of treatment adherence in older patients with Parkinson's disease.

Authors:  Jacquelyn L Bainbridge; J Mark Ruscin
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 7.  Compliance with medication in nursing homes for older people: resident enforcement or resident empowerment?

Authors:  Carmel M Hughes
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 8.  Treatment of advanced Parkinson's disease.

Authors:  Juan C Giugni; Michael S Okun
Journal:  Curr Opin Neurol       Date:  2014-08       Impact factor: 5.710

9.  Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.

Authors:  Kapil D Sethi; Robert A Hauser; Stuart H Isaacson; Terry McClain
Journal:  Cases J       Date:  2009-07-30

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.